{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:51:36Z","timestamp":1788580296851,"version":"build-2803163510"},"reference-count":8,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v106.adv-2025-0139","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:29:56Z","timestamp":1769066996000},"source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported Itch Outcome Measures for Chronic Pruritus in Dystrophic Epidermolysis Bullosa: Exploratory Analysis of a Phase 2 Randomized Controlled Trial"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0540-1711","authenticated-orcid":false,"given":"Utako","family":"Okata-Karigane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Gorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirunthan","family":"Pathmarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"139441","doi-asserted-by":"crossref","unstructured":"de Vere Hunt I, Halley M, Sum K, Yekrang K, Phung M, Good J, et al. A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa. Br J Dermatol 2022; 187: 261\u2013263.","DOI":"10.1111\/bjd.21031"},{"key":"139442","doi-asserted-by":"crossref","unstructured":"Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol 2015; 32: 53\u201359.","DOI":"10.1111\/pde.12391"},{"key":"139443","doi-asserted-by":"crossref","unstructured":"Korte EWH, Welponer T, Kottner J, van der Werf S, van den Akker PC, Horv\u00e1th B, et al. Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: A scoping review as a first step towards outcome harmonization. Br J Dermatol 2023; 189: 80\u201390.","DOI":"10.1093\/bjd\/ljad077"},{"key":"139444","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Lai JS, Kantor RW, Dalal P, Hickey C, Shaunfield S, et al. Development, validation, and interpretation of the PROMIS Itch Questionnaire: A patient-reported outcome measure for the quality of life impact of itch. J Invest Dermatol 2020; 140: 986\u2013994.","DOI":"10.1016\/j.jid.2019.08.452"},{"key":"139445","doi-asserted-by":"crossref","unstructured":"Haest C, Casaer MP, Daems A, De Vos B, Vermeersch E, Morren MA, et al. Measurement of itching: Validation of the Leuven Itch Scale. Burns 2011; 37: 939\u2013950.","DOI":"10.1016\/j.burns.2011.04.007"},{"key":"139446","doi-asserted-by":"crossref","unstructured":"Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59: 234\u2013244.","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"139447","doi-asserted-by":"crossref","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument. Br J Dermatol 2009; 161: 1323\u20131330.","DOI":"10.1111\/j.1365-2133.2009.09347.x"},{"key":"139448","doi-asserted-by":"crossref","unstructured":"Okata-Karigane U, Pathmarajah P, Gorell ES, Sum K, Yekrang K, Phung M, et al. Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial. J Eur Acad Dermatol Venereol 2025; 39: e215\u2013e217.","DOI":"10.1111\/jdv.20189"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45448\/52632","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45448\/52633","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45448\/52634","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45448\/52632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:30:11Z","timestamp":1769067011000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/45448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":8,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0139","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}